PATHEON N.V. Financial Statements (2026 and earlier)

Company Profile

Business Address EVERT VAN DE BEEKSTRAAT 104
AMSTERDAM SCHIPHOL, 1118 CN
State of Incorp.
Fiscal Year End October 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)
Annual | Quarterly

4/30/2017
MRQ
10/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 166
Cash and cash equivalent 165
Short-term investments 1
Receivables 410
Inventory, net of allowances, customer advances and progress billings 395
Inventory 395
Other undisclosed current assets 20
Total current assets: 991
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization 984
Long-term investments and receivables 12
Long-term investments 12
Intangible asset, including goodwill, after accumulated amortization 529
Goodwill 282
Intangible asset, excluding goodwill, after accumulated amortization 248
Other noncurrent assets 44
Other undisclosed noncurrent assets 80
Total noncurrent assets: 1,649
TOTAL ASSETS: 2,640
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 394
Interest and dividends payable 14
Taxes payable 7
Employee-related liabilities 82
Accounts payable 279
Accrued liabilities 9
Other undisclosed accounts payable and accrued liabilities 3
Debt 20
Deferred revenue and credits 154
Other undisclosed current liabilities 7
Total current liabilities: 574
Noncurrent Liabilities
Long-term debt and lease obligation, including: 2,100
Other undisclosed long-term debt and lease obligation 2,100
Liabilities, other than long-term debt 248
Deferred revenue and credits 102
Other liabilities 146
Other undisclosed noncurrent liabilities 67
Total noncurrent liabilities: 2,414
Total liabilities: 2,988
Equity
Equity, attributable to parent (348)
Common stock 2
Additional paid in capital 591
Accumulated other comprehensive loss (99)
Accumulated deficit (842)
Total equity: (348)
TOTAL LIABILITIES AND EQUITY: 2,640

Income Statement (P&L) ($ in millions)
Annual | Quarterly

4/30/2017
TTM
10/31/2016
Revenues
(Revenue, Net)		 1,867
Cost of revenue
(Cost of Product and Service Sold)		 (1,321)
Gross profit: 546
Operating expenses (332)
Other operating income, net 1
Other undisclosed operating loss (17)
Operating income: 198
Nonoperating expense (5)
Loss, foreign currency transaction, before tax (6)
Other nonoperating income 1
Interest and debt expense (22)
Income from continuing operations before equity method investments, income taxes: 171
Other undisclosed loss from continuing operations before income taxes (160)
Income from continuing operations before income taxes: 11
Income tax benefit 24
Income from continuing operations: 35
Income before gain (loss) on sale of properties: 35
Net income: 35
Other undisclosed net loss attributable to parent (3)
Net income available to common stockholders, diluted: 32

Comprehensive Income ($ in millions)
Annual | Quarterly

4/30/2017
TTM
10/31/2016
Net income: 35
Other comprehensive loss (76)
Comprehensive loss: (41)
Other undisclosed comprehensive income, net of tax, attributable to parent 47
Comprehensive income, net of tax, attributable to parent: 6

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: